Deltex Medical Group Plc (LON:DEMG) CFO Jonathan Shaw talks to DirectorsTalk about a trading update and a platform account RNS. Jonathan tells us a little more about the two hospitals that have signed up to the Deltex technology, what hitting 30 platform accounts means for Deltex and talks us through the highlights of the trading update.
Jonathan Shaw has spent the majority of his career working at either director or senior manager level in professional accounting and auditing firms most recently with Grant Thornton UK LLP in London and including PricewaterhouseCoopers LLP in Southampton where he was the company’s senior audit manager for nearly four years. During his career Mr Shaw has undertaken a number of secondments to industry or government and spent almost three years at the Financial Reporting Council, the UK’s independent regulator responsible for promoting high quality corporate governance and reporting to foster investment.
Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring (“ODM”), announced that it has added two new accounts to its platform programme in the USA. Both new hospitals are in the North-East, one with 300 and the second with 400 beds. The hospitals expect to use 40 and 50 probes a month once they have completed their initial implementation programmes which are scheduled to start in January and February respectively. The two new hospitals are the 29th and 30th US platform programme accounts and the 7th and 8th in the North-East territory. The company is recruiting an additional clinical trainer to support hospitals implementing ODM in this territory.